BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19776663)

  • 1. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein.
    Weiss J; Sauer A; Herzog M; Böger RH; Haefeli WE; Benndorf RA
    Pharmacology; 2009; 84(5):264-70. PubMed ID: 19776663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
    Weiss J; Haefeli WE
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
    Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
    J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation.
    Yousif S; Chaves C; Potin S; Margaill I; Scherrmann JM; Declèves X
    J Neurochem; 2012 Nov; 123(4):491-503. PubMed ID: 22845665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
    Kowalski P; Surowiak P; Lage H
    Mol Ther; 2005 Apr; 11(4):508-22. PubMed ID: 15771954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
    Weiss J; Sauer A; Divac N; Herzog M; Schwedhelm E; Böger RH; Haefeli WE; Benndorf RA
    Biopharm Drug Dispos; 2010 Mar; 31(2-3):150-61. PubMed ID: 20222053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
    Leggas M; Panetta JC; Zhuang Y; Schuetz JD; Johnston B; Bai F; Sorrentino B; Zhou S; Houghton PJ; Stewart CF
    Cancer Res; 2006 May; 66(9):4802-7. PubMed ID: 16651435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of alkoxyl biphenyl derivatives bearing dibenzo[c,e]azepine scaffold as potential dual inhibitors of P-glycoprotein and breast cancer resistance protein.
    Gu X; Tang X; Zhao Q; Peng H; Peng S; Zhang Y
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3419-21. PubMed ID: 24928398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
    Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
    J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
    Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M
    Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
    Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATP binding cassette transporters in two distinct compartments of the skin contribute to transdermal absorption of a typical substrate.
    Hashimoto N; Nakamichi N; Uwafuji S; Yoshida K; Sugiura T; Tsuji A; Kato Y
    J Control Release; 2013 Jan; 165(1):54-61. PubMed ID: 23089896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).
    Tournier N; Chevillard L; Megarbane B; Pirnay S; Scherrmann JM; Declèves X
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):905-15. PubMed ID: 19887017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate.
    Kodaira H; Kusuhara H; Fujita T; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2011 Dec; 339(3):935-44. PubMed ID: 21934030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of efflux transporters involved in distribution and disposition of apixaban.
    Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
    Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.